Stroke Prognosis via Marker Peptide Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical diagnostics for stroke patients lack effective methods for early and accurate prognosis of outcomes and risk assessment, particularly in differentiating between ischemic and hemorrhagic strokes, and predicting future cardiovascular events.
Innovation Solution
An in vitro method involving the determination of specific marker peptides such as ANP, AVP, ADM, ET-1, calcitonin, and hGH in patient samples, combined with multivariate analysis and capture probes, to assess the risk of stroke, transient ischemic attack, and predict functional outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Difficulty of detecting and measuring
If neuroradiological imaging methods like CT or MRT are used for stroke diagnosis, then diagnostic capability is improved, but measurement precision for prognosis and risk assessment deteriorates
Solution Approach 1:
The invention segments the diagnostic process into two distinct phases: diagnostic phase (using CT/MRT for detecting stroke presence) and prognostic phase (using marker peptide levels for predicting outcomes). This segmentation allows each method to be optimized for its specific purpose, resolving the contradiction between diagnostic capability and prognosis precision.
Solution Approach 2:
The invention introduces marker peptides (ANP, BNP, NT-proBNP) as intermediary substances that mediate between the physical stroke event and the clinical outcome prediction. These peptides serve as biochemical messengers that provide precise prognostic information complementary to imaging-based diagnosis.
2Device complexity
If single marker peptide determination is used, then method simplicity is improved, but prognosis accuracy deteriorates
Solution Approach 1:
The invention merges multiple marker peptide determinations (ANP, BNP, NT-proBNP) into a single integrated prognostic assessment method. The combination of these complementary markers provides synergistic information that improves prognosis accuracy beyond what any single marker could achieve alone.
Solution Approach 2:
The prognostic method uses a composite approach by combining multiple biochemical markers (ANP, BNP, NT-proBNP) to create a more robust and accurate prediction system, analogous to using composite materials that combine different properties for enhanced performance.
3Loss of time
If rapid differential diagnosis is implemented, then treatment time is improved, but measurement precision for individual prognosis deteriorates
Solution Approach 1:
The invention performs preliminary rapid differential diagnosis using standard imaging methods to establish the stroke type, then immediately follows up with marker peptide determination to refine individual prognosis. This preliminary action sequence ensures both rapid initial response and precise subsequent personalized care.
Solution Approach 2:
The diagnostic approach is made dynamic by implementing a two-stage process that adapts to clinical needs: rapid initial diagnosis followed by detailed prognostic assessment. This dynamic approach allows the system to balance speed and precision based on the specific clinical situation and patient needs.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a method for prognosis of an outcome or assessing the risk of a patient having suffered a stroke or a transient ischemic attack, comprising the determination of the level of at least one marker peptide in said sample said marker peptide selected from the group comprising ANP, AVP, ADM, ET-1, troponin, CRP, calcitonin and hGH or fragments thereof or its precursor or fragments thereof and attributing the level of said at least one marker peptides its precursor or fragments thereof with the prognosis of an outcome or assessing the risk for said patient.